China Opens Doors to Domestic Rivals After Novo Nordisk Patent Lapse, Sparking Weight‑Loss Drug Rush
Novo Nordisk’s semaglutide lost patent protection in China on March 20, triggering at least 10 domestic weight‑loss drugs to seek approval as regulators speed up drug clearances. The market could reach about US$14 billion by 2030.